Telitacicept for Injection

Tetasip is an innovative drug independently developed in China. It is used in combination with conventional treatment for adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who still have high disease activity on the basis of conventional treatment. Tetasip was conditionally approved for marketing in China in March 2021. [1]
Mechanism of Action
Tetasip for injection is a fusion protein constructed by combining the extracellular specific soluble part of the transmembrane protein activator (TACI) of the B lymphocyte stimulator (BLyS) receptor with the crystallizable fragment (Fc) of human immunoglobulin G1 (IgG1). Since the TACI receptor has a high affinity for BLyS and proliferation-inducing ligand (APRIL), Tetasip can prevent the interaction between BLyS and APRIL and their cell membrane receptors, B cell maturation antigens, and B cell activation molecule receptors, thereby inhibiting the biological activity of BLyS and APRIL. The launch of this product provides patients with a new treatment option. [1]
Indications
Combined with conventional treatment, it is suitable for adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with high disease activity despite conventional treatment. [1]
Clinical studies
Tetasip is a new dual-targeted biological drug targeting BLyS and APRIL. This study achieved the primary clinical endpoint, and the main clinical indicators were significantly improved compared with existing drugs. It is a major breakthrough in the treatment of systemic lupus erythematosus and is of great significance. [2]